Summit beats Merck in late-stage lung cancer trial

Plus: Summit's iconoclastic billionaire CEO, Robert Duggan

September 10, 2024 Check out STAT+

Sponsored By

PASCAL POCHARD-CASABIANCA/AFP via Getty Images STAT+ | Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial Summit's treatment reduced the risk of tumor progression by 49% compared to the standard of care. By Jonathan Wosen and Adam Feuerstein STAT+ | With a win in lung cancer, biotech's wealthiest outsider surfs to new heights Summit's lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in biotech. By Matthew Herper STAT+ | Merck executive plays down impact of new lung cancer drug data on Keytruda "I see these results as important, but preliminary," Chief Medical Officer Eliav Barr told STAT, reacting to a Phase 3 clinical trial involving ivonescimab. By Adam Feuerstein National Cancer Institute/Massey Cancer Center at Virginia Commonwealth Univ. STAT+ | Relay discloses encouraging results for experimental breast cancer treatment Relay is planning a late-stage trial comparing its breast cancer drug to a rival treatment from AstraZeneca. By Angus Chen She was told she might have cancer: How medicine pathologizes Black patients' normal test results "Embedded Bias" is a STAT investigation of race in medical algorithms. Part 5 looks at benign ethnic neutropenia, a problematic diagnosis. By Usha Lee McFarling

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser